Axel Haupt (A Haupt)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Topics

Combination Therapy

Insulin Resistance

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

Diabetic medicine : a journal of the British Diabetic Association

This page only lists publications with an associated author ORCID identifier.

Publications

Filip K Krag Knop, Shweta Urva, Mallikarjuna Rettiganti, Charles T Benson, William C Roell, Kieren J Mather, Axel Haupt, Edward John Pratt
A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes, obesity & metabolism (2024)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Melissa K Thomas, Kieren J Mather, Chrisanthi A Karanikas, Julia P Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care (2023)
Kieren J Mather, Tamer Coskun, Edward John Pratt, Zvonko Milicevic, Govinda Weerakkody, Melissa K Thomas, Axel Haupt, Giacomo Ruotolo
Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes. Diabetes, obesity & metabolism (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Edward John Pratt, Xiaosu Ma, Rong Liu, Deborah Robins, Tamer Coskun, Kyle W Sloop, Axel Haupt, Charles Benson
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes, obesity & metabolism (2023)
Shweta Urva, Libbey O'Farrell, Yu Du, Mei Teng Loh, Andrea Hemmingway, Hongchang Qu, Jorge Alsina-Fernandez, Axel Haupt, Zvonko Milicevic, Tamer Coskun
The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, obesity & metabolism (2023)
Edward John Pratt, Xiaosu Ma, Rong Liu, Deborah Robins, Axel Haupt, Tamer Coskun, Kyle W Sloop, Charles Benson
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes, obesity & metabolism (2023)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism (2022)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel Basal Insulin Fc (BIF, insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes mellitus. Diabetes, obesity & metabolism (2022)
Tim Heise, Jenny Chien, John M Beals, Charles Benson, Oliver Klein, Julie S Moyers, Axel Haupt, Edward John Pratt
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes, obesity & metabolism (2022)
Jonathan M Wilson, Yanzhu Lin, M Jane Luo, Gary Considine, Amy L Cox, Lenden M Bowsman, Deborah A Robins, Axel Haupt, Kevin L Duffin, Giacomo Ruotolo
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 24 (1) (2021)
Shweta Urva, Tamer Coskun, Corina Loghin, Xuewei Cui, Emily Beebe, Libbey O'Farrell, Daniel A Briere, Charles Benson, Michael A Nauck, Axel Haupt
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, obesity & metabolism 22 (10) (2020)
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, obesity & metabolism 22 (6) (2020)
Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer, Axel Haupt, Kevin L Duffin, Marja-Riitta Taskinen, Giacomo Ruotolo
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (12) (2020)
Francesco Giorgino, Maria Yu, Axel Haupt, Zvonko Milicevic, Luis-Emilio Garcia-Perez
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial. Diabetes, obesity & metabolism 21 (11) (2019)
Chantal Mathieu, Stephano Del Prato, Fady T Botros, Vivian T Thieu, Imre Pavo, Nan Jia, Axel Haupt, Chrisanthi A Karanikas, Luis-Emilio Garcia-Perez
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. Diabetes, obesity & metabolism 20 (8) (2018)
K Cusi, N Sattar, L-E García-Pérez, I Pavo, M Yu, K E Robertson, C A Karanikas, Axel Haupt
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabetic medicine : a journal of the British Diabetic Association 35 (10) (2018)